Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) EBT (2018 - 2026)

10x Genomics' EBT history spans 8 years, with the latest figure at -$15.2 million for Q4 2025.

  • On a quarterly basis, EBT rose 68.6% to -$15.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$39.9 million, a 77.54% increase, with the full-year FY2025 number at -$39.9 million, up 77.54% from a year prior.
  • EBT hit -$15.2 million in Q4 2025 for 10x Genomics, up from -$28.2 million in the prior quarter.
  • Over the last five years, EBT for TXG hit a ceiling of $37.0 million in Q2 2025 and a floor of -$91.7 million in Q3 2023.
  • Historically, EBT has averaged -$34.1 million across 5 years, with a median of -$35.8 million in 2024.
  • Biggest five-year swings in EBT: tumbled 541.0% in 2022 and later soared 199.78% in 2025.
  • Tracing TXG's EBT over 5 years: stood at -$16.0 million in 2021, then decreased by 2.61% to -$16.4 million in 2022, then plummeted by 183.94% to -$46.6 million in 2023, then decreased by 3.82% to -$48.4 million in 2024, then surged by 68.6% to -$15.2 million in 2025.
  • Business Quant data shows EBT for TXG at -$15.2 million in Q4 2025, -$28.2 million in Q3 2025, and $37.0 million in Q2 2025.